RE-BVS – Piemonte Repository

Sfoglia per AUTORE
GRANETTO C
Collezione AO Cuneo

Items : 14

Circulating cytokines and outcome in metastatic colorectal cancer patients treated with regorafenib. in World journal of gastrointestinal oncology / World J Gastrointest Oncol. 2020 Mar 15;12(3):301-310. doi: 10.4251/wjgo.v12.i3.301.

2020
AO Cuneo

Ricci V; Granetto C; Falletta A; Paccagnella M; Abbona A; Fea E; Fabozzi T; Lo Nigro C; Merlano MC; Ricci V; Granetto C; Falletta A; Paccagnella M; Abbona A; Fea E; Fabozzi T; Lo Nigro C; Merlano MC;

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. in The Lancet. Oncology / Lancet Oncol. 2020 Apr;21(4):497-507. doi: 10.1016/S1470-2045(19)30862-9. Epub 2020 Mar 9.

2020
AO Cuneo
AOU Città della Salute di Torino

Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Falcone A; Boni L; Zagonel V; Ugolini C; Fontanini G; Corgna E; Cupini S; Mammoliti S; Fenocchio E; Roselli M; Mambrini A; Ritorto G; Di Donato S; Clavarezza M; Carlomagno C; Ronzoni M; Tomasello G; Masi G; Antonuzzo L; Cordio S; Moretto R; Corallo S; Granetto C; Buonadonna A; Zaniboni A; et alii...

Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2019 Mar;109:175-182. doi: 10.1016/j.ejca.2018.12.028. Epub 2019 Feb 5.

2019
AO Cuneo

Lonardi S; Sensi E; Tonini G; Di Donato S; Schirripa M; Delfanti S; Granetto C; Gemma D; Casagrande M; Borelli B; Allegrini G; Murgioni S; Antoniotti C; Dell'Aquila E; Salvatore L; Masi G; Aprile G; Bergamo F; Cremolini C; Marmorino F; Fontanini G; Boni L; Falcone A;

Discontinuation of first-line bevacizumab in metastatic colorectal cancer: the BEAWARE Italian Observational Study. in Tumori / Tumori. 2019 Jun;105(3):243-252. doi: 10.1177/0300891619834126. Epub 2019 Mar 11.

2019
AO Cuneo
AOU Città della Salute di Torino

Tonini G; Bergamo F; Proietti E; Proserpio I; Ballestrero A; Biglietto M; Lucchesi S; Granetto C; Ciuffreda L; Fagnani D; Gemma D; Nasti G; Lonardi S;

Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2018 Jul;29(7):1528-1534. doi: 10.1093/annonc/mdy140. Epub 2018 Apr 20.

2018
AO Cuneo
AOU Città della Salute di Torino

Falcone A; Fontanini G; Boni L; Sensi E; Zagonel V; Masi G; Allegrini G; Granetto C; Buonadonna A; Marmorino F; Tonini G; Zaniboni A; Loupakis F; Ronzoni M; Racca P; Moretto R; Cortesi E; Tomasello G; Lonardi S; Bergamo F; Antoniotti C; Cremolini C; Cremolini C; Antoniotti C; Lonardi S; Bergamo F; Cortesi E; Tomasello G; Moretto R; et alii...

TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer. in ESMO open / ESMO Open. 2018 Jul 9;3(4):e000403. doi: 10.1136/esmoopen-2018-000403. eCollection 2018.

2018
AO Cuneo

Borelli B; Moretto R; Lonardi S; Bonetti A; Antoniotti C; Pietrantonio F; Masi G; Burgio V; Marmorino F; Salvatore L; Rossini D; Zaniboni A; Zucchelli G; Martignetti A; Di Battista M; Pella N; Passardi A; Boccaccino A; Leone F; Colombo C; Granetto C; Vannini F; Marsico VA; Martinelli E; Antonuzzo L; Vitello S; Delliponti L; Boni L; Cremolini C; et alii...

Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2017 Mar;73:74-84. doi: 10.1016/j.ejca.2016.10.028. Epub 2016 Dec 13.

2017
AO Cuneo

Cremolini C; Casagrande M; Loupakis F; Aprile G; Bergamo F; Masi G; Moretto R R; Pietrantonio F; Marmorino F; Zucchelli G; Tomasello G; Tonini G; Allegrini G; Granetto C; Ferrari L; Urbani L; Cillo U; Pilati P; Sensi E; Pellegrinelli A; Milione M; Fontanini G; Falcone A;

Heterogeneity of colon cancer: from bench to bedside. in ESMO open / ESMO Open. 2017 Aug 22;2(3):e000218. doi: 10.1136/esmoopen-2017-000218. eCollection 2017.

2017
AO Cuneo

Merlano MC; Granetto C; Fea E; Ricci V; Garrone O;

Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer. in British journal of cancer / Br J Cancer. 2016 Sep 27;115(7):789-96. doi: 10.1038/bjc.2016.271. Epub 2016 Sep 6.

2016
AO Cuneo

Dalgleish AG; Stebbing J; Adamson DJ; Arif SS; Bidoli P; Chang D; Cheeseman S; Diaz-Beveridge R; Fernandez-Martos C; Glynne-Jones R; Granetto C; Massuti B; McAdam K; McDermott R; Martín AJ; Papamichael D; Pazo-Cid R; Vieitez JM; Zaniboni A; Carroll KJ; Wagle S; Gaya A; Mudan SS;

FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2016 May;27(5):843-9. doi: 10.1093/annonc/mdw052. Epub 2016 Feb 9.

2016
AO Cuneo
AOU Città della Salute di Torino

Bustreo S; Ronzoni M; Buonadonna A; Bergamo F; Tomasello G; Tonini G; Allegrini G; Vitello S; Rossini D; Moretto R; Chiara S; Mancini ML; Granetto C; Lonardi S; Masi G; Loupakis F; Cremolini C; Barbara C; Boni L; Falcone A;

Evaluation of antibody-dependent cell-mediated cytotoxicity activity and cetuximab response in KRAS wild-type metastatic colorectal cancer patients. in World journal of gastrointestinal oncology / World J Gastrointest Oncol. 2016 Feb 15;8(2):222-30. doi: 10.4251/wjgo.v8.i2.222.

2016
AO Cuneo

Lo Nigro C; Ricci V; Vivenza D; Monteverde M; Strola G; Lucio F; Tonissi F; Miraglio E; Granetto C; Fortunato M; Merlano MC;

Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy. in World journal of gastroenterology / World J Gastroenterol. 2016 Aug 14;22(30):6944-54. doi: 10.3748/wjg.v22.i30.6944.

2016
AO Cuneo

Lo Nigro C; Ricci V; Vivenza D; Granetto C; Fabozzi T; Miraglio E; Merlano MC;

Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2015 Jun;26(6):1188-1194. doi: 10.1093/annonc/mdv112. Epub 2015 Feb 23.

2015
AO Cuneo
AOU Città della Salute di Torino

Di Donato S; Granetto C; Bonetti A; D'Amico M; Vitello S; Longarini R; Barone C; Tonini G; Spadi R; Zaniboni A; Tomasello G; Cortesi E; Salvatore L; Masi G; Lonardi S; Antoniotti C; Cremolini C; Loupakis F; Boni L; Falcone A;

Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2015 Apr;26(4):724-730. doi: 10.1093/annonc/mdv012. Epub 2015 Jan 18.

2015
AO Cuneo

Masi G; Salvatore L; Boni L; Loupakis F; Cremolini C; Fornaro L; Schirripa M; Cupini S; Barbara C; Safina V; Granetto C; Fea E; Antonuzzo L; Boni C; Allegrini G; Chiara S; Amoroso D; Bonetti A; Falcone A;